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Background: Plasmodium vivax is the most prevalent malaria species in Pakistan, with a distribution that coincides
with Plasmodium falciparum in many parts of the country. Both species are likely exposed to drug pressure from a
number of anti-malarials including chloroquine, sulphadoxine-pyrimethamine (SP), and artemisinin combination
therapy, yet little is known regarding the effects of drug pressure on parasite genes associated with drug resistance.
The aims of this study were to determine the prevalence of polymorphisms in the SP resistance-associated genes
pvdhfr, pvdhps and chloroquine resistance-associated gene pvmdr1 in P. vivax isolates collected from across the
country.
Methods: In 2011, 801 microscopically confirmed malaria-parasite positive filter paper blood samples were
collected at 14 sites representing four provinces and the capital city of Islamabad. Species-specific polymerase chain
reaction (PCR) was used to identify human Plasmodium species infection. PCR-positive P. vivax isolates were
subjected to sequencing of pvdhfr, pvdhps and pvmdr1 and to real-time PCR analysis to assess pvmdr1 copy number
variation.
Results: Of the 801 samples, 536 were determined to be P. vivax, 128 were P. falciparum, 43 were mixed vivax/
falciparum infections and 94 were PCR-negative for Plasmodium infection. Of PCR-positive P. vivax samples, 372
were selected for sequence analysis. Seventy-six of the isolates (23%) were double mutant at positions S58R and
S117N in pvdhfr. Additionally, two mutations at positions N50I and S93H were observed in 55 (15%) and 24 (7%) of
samples, respectively. Three 18 base pair insertion-deletions (indels) were observed in pvdhfr, with two insertions at
different nucleotide positions in 36 isolates and deletions in 10. Ninety-two percent of samples contained the
pvdhps (S382/A383G/K512/A553/V585) SAKAV wild type haplotype. For pvmdr1, all isolates were wild type at
position Y976F and 335 (98%) carried the mutation at codon F1076L. All isolates harboured single copies of the
pvmdr1 gene.
Conclusions: The prevalence of mutations associated with SP resistance in P. vivax is low in Pakistan. The high
prevalence of P. vivax mutant pvmdr1 codon F1076L indicates that efficacy of chloroquine plus primaquine could
be in danger of being compromised, but further studies are required to assess the clinical relevance of this
observation. These findings will serve as a baseline for further monitoring of drug-resistant P. vivax malaria in
Pakistan.
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Malaria imposes a significant public health burden in
Pakistan, causing a reported 1.6 million cases per year
according to the World Health Organization (WHO) [1].
Plasmodium vivax is the most prevalent species of human
malaria in the country, accounting for 200,000 (67%) of all
cases in 2011 [2], with Plasmodium falciparum malaria ac-
counting for the remaining one-third. Chloroquine plus
primaquine is the first-line treatment for P. vivax in most of
the world, including Pakistan. After the rise of chloroquine
resistance in P. falciparum, sulphadoxine-pyrimethamine
(SP) treatment became widespread throughout Asia and has
since been replaced by artesunate plus SP for treatment of
falciparum malaria in Pakistan. Despite its prevalence and
public health importance, P. vivax has not been well-
characterized with respect to drug resistance to chloroquine
or to SP (to which it may be exposed during presumptive
treatment of P. falciparum) in Pakistan [3].
Chloroquine resistance in P. vivax has been observed
in the Pacific [4], Latin America [5], and parts of Asia
[6,7] but has not yet been reported in Pakistan and
Afghanistan [8,9], and chloroquine remains effective
against P. vivax in India [10,11]. Chloroquine resistance
in P. vivax is thought to be mediated by single nucleo-
tide polymorphisms (SNPs) in the pvmdr1 gene of P.
vivax [12-14]. It has been suggested that point mutations
at codons Y976F and F1076L of the pvmdr1 gene may
be involved in resistance to 4-aminoquinolones, chloro-
quine and amodiaquine [12,15]. In vitro data show that
Indonesian P. vivax isolates with a prevalence of 96% for
mutation Y976F had a significantly higher IC50 for
chloroquine compared to Thai isolates, which had a 25%
prevalence of Y976F [16]. Whereas an association of
mutation F1076L with chloroquine resistance has not
yet been found [16,17], the most common pvmdr1 hap-
lotypes found in nature are F1076L [18-20], and Y976F
plus F1076L [21], with the single mutantY976F reported
only rarely [16]. This observation has given rise to the
theory that a two-step mutational trajectory, with muta-
tions at codon F1076L followed by Y976F, may lead to
chloroquine resistance [12,22]; however, in vivo substan-
tiation of this theory is required. Polymorphisms in copy
number of the pvmdr1 gene may also modulate drug re-
sistance in P. vivax, as shown by a link between gene
amplification and decreased in vitro susceptibility to
mefloquine, artesunate, and amodiaquine but increased
susceptibility to chloroquine [23].
Although SP has not been indicated for treatment of
P. vivax, there is evidence that intensive SP use for treat-
ment of P. falciparum may also select for resistant P.
vivax in regions where both species coexist [24-26]. An
efficacy study of SP, chlorproguanil-dapsone and chloro-
quine carried out from 2004 to 2006 suggests that
antifolates were effective against P. vivax in Afghanistanand Pakistan at that time [9]. In the absence of more re-
cent data, molecular markers may be used to monitor
the effects of SP pressure on P. vivax.
Pyrimethamine and sulphadoxine target the dhfr and
dhps enzymes in P. falciparum and point mutations in
these genes confer resistance to each drug [27-34]. Mu-
tations in codons I13L, P33L, F57L/I, S58R, T61M,
S117N/T and I173L/F of the P. vivax dhfr enzyme have
been proposed as conferring similar resistance to pyri-
methamine in P. vivax [19,35]. In vitro studies of pvdhfr
expression in Escherichia coli, P. falciparum and
yeast have shown that pvdhfr double and triple mutants
S58R + S117N, F57L + S58R, and F57L + S58R + S117T
confer significant (up to several hundred-fold) reduc-
tions in susceptibility to antifolates [36-39] and are asso-
ciated with reduced drug affinity to the target enzyme
[38]. In P. vivax dhps, mutations at codons S382A/C,
A383G, K512M/T/E, and A553G/C are hypothesized to
confer resistance to sulphadoxine [25,40].
In Pakistan, published data are not available on the
prevalence of point mutations in pvmdr1, and limited in-
formation is available regarding the prevalence of muta-
tions in pvdhfr and pvdhps. In 2009, a study conducted
in Bannu district of Pakistan reported a prevalence of
1.7% of pvdhfr F57L, 19% for S58R and 93.5% for S117N
[3]. In pvdhps, a study conducted in 2010 in the Feder-
ally Administered Tribal Areas of Khyber Pakhtunkhwa
province reported that 15% of samples had A383G and
54% had A553G/C [41]. Because up to date information
on clinical efficacy and molecular markers of anti-
malarial resistance in Pakistan is not available, this study
was designed to evaluate the current prevalence of point
mutations in pvdhfr, pvdhps and pvmdr1 genes of P.
vivax in 14 sites around the country. The results
presented here provide indications of whether efficacy of
current anti-malarials is being maintained against P.
vivax in Pakistan or requires further assessment.
Methods
Sample collection and ethics
Twenty-five government and private hospitals in the
four provinces with the highest malaria burden (Khyber
Pakhtunkhwa, Sindh, Balochistan and Punjab) along
with the capital city were invited to provide samples col-
lected during routine malaria surveillance. Fourteen fa-
cilities responded and were included in this study:
Islamabad (the capital), Peshawar, Thall, Bannu and
Hangu (Khyber Pakhtunkhwa Province; KPK), Karachi
and Hyderabad (Sindh Province), Zhob and Quetta (Ba-
lochistan Province), Rawalpindi, Bhakhar, Mainwali, La-
hore and Muzaffarghar (Punjab Province) (Figure 1)
[42]. Despite the high prevalence of malaria, the Feder-
ally Administered Tribal Areas were excluded from this
study because political uncertainty and terrorism [43]
Figure 1 Plasmodium vivax collection sites and sample sizes selected for sequencing. Total sample sizes by province were as follows:
Khyber Pakhtunkhwa (119), Islamabad (50), Punjab (103), Balochistan (50) and Sindh (50).
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were collected between April and October 2011. A total
of 10,782 symptomatic patients of all ages presenting
with signs of malaria was screened for malaria infection
by microscopic examination of blood by a trained la-
boratory technician. Approximately 3 ml of venous
blood was drawn in EDTA tubes from each patient for
suspected cases after obtaining informed consent. Infor-
mation on patient age, gender, and city of residence was
collected. The study was approved by the institutional
review board of Quaid-i-Azam University, Islamabad,
Pakistan.
Microscopy and dried blood spot collection
Thick and thin blood films of patients with suspected
malaria were stained with 10% Giemsa solution and
slides were examined at 100X under oil immersion of
microscope by laboratory technician/technologist trained
in malaria diagnosis in line with WHO guidelines [44].
For samples testing positive for malaria by microscopy,
50 μl blood was applied to Whatman 3MM filter paper.
Blood from 30 malaria-negative samples by microscopy
was also spotted on filter paper. The remaining blood
from all samples was stored on site at −80°C. Filterpapers were air-dried overnight and stored in individual
plastic bags with desiccant at room temperature.
DNA extraction and speciation
DNA was isolated from 801 malaria-positive by micros-
copy and 30 malaria-negative filter paper samples using
the QIAmp 96 DNA kit (Qiagen, Valencia, CA, USA).
Isolated DNA was stored at − 20°C for further analysis.
Plasmodium species (P. vivax, P. falciparum, P. ovale
and P. malariae) were confirmed by nested polymerase
chain reaction (PCR) amplification of the small subunit
ribosomal ribonucleic acid (ssrRNA) genes using primers
and thermal cycler conditions as previously described
[45]. Twenty-seven of the 30 microscopy-negative sam-
ples were also subjected to PCR for quality control. PCR
products were visualized by 2-2.5% agarose gel electro-
phoresis using the Bio-Rad gel doc system (Bio-Rad,
Hercules, CA, USA). Molecular analysis was conducted
at the University of Maryland School of Medicine, Balti-
more, USA.
Amplification of pvdhfr, pvdhps and pvmdr1
Out of 579 PCR-confirmed (536 P. vivax and 43 P.
vivax/P. falciparum mixed infection) samples, 372
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characterization (Table 1). Target sequences of the
pvdhfr, pvdhps and pvmdr1 genes harbouring known or
putative mutations associated with SP and chloroquine
resistance were selected for nested PCR amplification
and sequencing. Primers, reagent concentrations and
thermal cycling conditions were adapted from those pre-
viously published [19] with the following modifications.
Denaturation was done at 94°C for 30 sec, 2 μl of DNA
template was added to a total reaction volume of 50 μl,
and the second round of PCR was carried out for a total
of 25 cycles. PCR products were visualized as previously
described. The expected band sizes for pvdhfr, pvdhps
and pvmdr1 were 632, 767 and 547 bp, respectively.Table 1 Prevalence of multilocus genotypes and single
nucleotide polymorphism in pvdhfr, pvdhps and pvmdr1
gene of P. vivax
Gene Sample size Haplotypes* No of isolates
(%)




































*Drug resistance conferring point mutations are shown for the following
codons: pvdhfr 13, 33, 57, 58, 61, 117, 173; pvdhps 382, 383, 512, 553, 585; and
pvmdr1 976, 1076. Mutated amino acids are shown in bold.Sequencing
Amplified secondary PCR products of pvdhfr, pvdhps
and pvmdr1 genes were purified using Millipore® fil-
tration plates (EMD Millipore, Billerica, MA, USA).
The sequencing reaction for all three genes was
performed in the forward and reverse directions using
secondary PCR primers. The BigDye terminator v3.1
kit (ABI) was used for each sequencing reaction in
the following ratios: BigDye 1 μl, buffers 1 μl, 2 μmol
of nested PCR forward or reverse primers, purified
PCR products 2 μl and ultra pure water 5 μl in a vol-
ume of 10 μl. The thermal cycler was programmed as
follows: 94°C for 20 min, 25 cycles of 94°C for
20 sec, 50°C for 5 sec, 48°C for 5 sec, 60°C for
3 min, and final extension at 60°C for 5 min. Sequen-
cing was performed using an ABI 3730XL automatic
sequencer (Applied Biosystems, Foster City, CA) and
sequence analyses and alignment was performed using
Sequencher 4.10.1 software (Gene Codes Corp., Ann
Arbor, MI, USA). Sequences of a P. vivax ARI/
Pakistan isolate (Gen-Bank accession no. X98123),
Brazilian clinical isolate (accession no AY186730) and
Sal-1 (Gen-Bank accession no. AY618622) were used
as references for polymorphisms in pvdhfr, pvdhps
and pvmdr1.Confirmation of rare variants
Rare or novel SNP variants were ruled out as PCR or
sequencing errors as follows. SNPs occurring in a sin-
gle sample and those not previously reported were re-
amplified by PCR and sequenced a second time to
confirm presence of the polymorphism. Original and
re-sequencing reactions were both conducted in the
forward and reverse directions (2X coverage) to re-
duce the likelihood of sequencing errors.Quantification of pvmdr1 copy number
Quantification of pvmdr1 copy number was assessed
using previously described primers, probes and ther-
mal cycler conditions [19] on a TaqMan 7700 real-
time PCR machine (Applied Biosystems, Warrington,
UK). Pvaldolase was used as the endogenous control
and a plasmid containing a single and double copy
number insert of pvmdr1 in pCR2.1 vector was used
as calibrator. All samples were run in triplicate.
pvmdr1 copy number values between 0.5 and 1.3
were considered as single copy, between 1.6 and 2.3
as two copies and between 2.6 and 3.3 as three cop-
ies. Assays were repeated if copy number values were
between 1.3 and 1.6 and 2.3 and 2.6. Assays were also
repeated if the Ct value exceeded 35 or the standard
deviation for replicates of pvmdr1 or pvaldolase copy
number exceeded 0.2. Copy number of pvmdr1 was
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Of 801 malaria-positive isolates by microscopy, PCR
analysis revealed that 536 (76%) isolates were positive
for P. vivax, 128 (18%) were P. falciparum, and 43 (4%)
were mixed infections of both P. falciparum plus P.
vivax. None of the samples was positive for P. malariae
or P. ovale and 94 samples were PCR-negative for Plas-
modium DNA. Results discordant with microscopic
diagnosis were re-tested by PCR for confirmation, and a
further comparison of microscopy and PCR results is
presented in a separate manuscript [42]. Age among the
801 subjects ranged from two months to 75 years, with
a median of 24 years. 64% of samples were collected
from males and 36% from females. The gender distribu-
tion was identical and age distribution nearly identical in
the subset of 372 of 579 P. vivax-positive samples by
PCR that were selected for sequencing (age range = two
months to 70 years; median = 25 years). Of these, se-
quencing was successful in 90% (336/372) for pvdhfr,
91% (339/372) for pvdhps and 92% (342/372) for
pvmdr1. A subset of 120 PCR-positive P. vivax isolates
was randomly selected for the quantification of pvmdr1
copy number variation, and the assay was successful in
108 (90%) of isolates.
Sequenced regions of each gene were monoclonal with
no evidence of mixtures of SNPs among any of the sam-
ples, allowing the investigators to identify haplotypes.
For codons I13L, P33L, F57L/I, S58R, T61M, S117N/T
and I173L/F of pvdhfr, 151 (45%) of the isolates had the
wild-type haplotype IPFSTSI. One hundred isolates
(30%) had the S117N single mutation, 76 (23%)
harboured S58R plus S117N double mutants, five iso-
lates had the F57L plus S58R double mutant and one
sample had the S58I plus S117N double mutant. The
two mutations responsible for conferring pyrimethamine
resistance in vitro, S58R and S117N, [46], were found in
84 (25%) and 177 (53%) of isolates, respectively. The
pvdhfr S58R plus S117N double mutant haplotype was
most prevalent among isolates in Sindh (6.8%) and Khy-
ber Pakhtunkhwa province (6.5%) (Table 2). Although
the pvdhfr double mutant was more common in infected
patients over the age of 12 years than in children aged
12 and under prevalence of 24% versus 15%, the differ-
ence was not statistically significant (chi-square = 1.87;
p = 0.17). Similarly, the double mutant was present in
28% of infections in females and 20% of in-
fections in males but the difference was not significant
(chi-square = 2.67; p = 0.10). Eight additional non-synonymous SNPs were detected, corresponding to
amino acids N50I, S57R, S58R, S58I, S93R, S93H,
S117N and N123K. Two of these, S93R and K123N, have
not been reported previously. Non-synonymous and syn-
onymous mutations are given in tabulated form in Add-
itional file 1.
Based on the use of P. vivax strain ARI/Pakistan
(GenBank accession no X98123) as reference for pvdhfr,
three indels were detected in the study, all 18 base pairs
(bp) in size (Table 3). Seven isolates had an 18 bp repeat
insertion between amino acid positions 91 and 92, and
21 samples had an 18 bp repeat insertion between co-
dons 103 and 104. Ten isolates were discovered with an
18-bp deletion between amino acids 92 and 97.
The majority of samples were wild-type for pvdhps
point mutations associated with sulphadoxine resistance,
with the exception of seven samples carrying the A383G
mutation, one carrying the A553G mutation, and one
carrying the A383G plus A553G double mutation
(Table 1). Four of the samples carrying the A383G muta-
tion were from Khyber Pakhtunkhwa while the other
three were found in each of three provinces, and the
A383G plus A553G double mutant was found in Punjab
(Table 2). Six non-synonymous mutations were detected
(Additional file 1), four of which have not been previ-
ously reported.
The three most prevalent pvdhfr plus pvdhps haplo-
types across all sites were wild-type (44%), single pvdhfr
mutantI13P33F57S58T61N 117I173/ S382A383K512A553V585
(30%) and double pvdhfr mutant I13P33F57R58T61N
117I173/ S382A383K512A553V585 (21%).
All isolates were wild type at pvmdr1 codon Y976F
while 335 (98%) isolates carried the point mutation at
codon F1076L (Table 1). One hundred and ten, or 32%
of all isolates with pvmdr1 F1076L, were found in Khy-
ber Pakhtunkhwa and 84 (25%) were found in Punjab
province. Three other non-synonymous SNPs (Y963C,
N1010S and S1071G) not previously reported and a sin-
gle synonymous SNP were also found (Additional file 1).
All 108 isolates tested carried a single copy of the
pvmdr1 gene.
Discussion
Pakistan adopted artesunate plus SP combination ther-
apy as a first line treatment against uncomplicated P. fal-
ciparum in 2008 [47]. Chloroquine is no longer
indicated for treatment of P. falciparum but is
recommended in combination with primaquine for treat-
ment of P. vivax. Although the nature of anti-malarial
use in Pakistan is not well-characterized, the availability
of SP and other drugs as monotherapy has been docu-
mented [48] and, along with misdiagnosis of mixed in-
fections [49] and presumptive treatment [50], likely
results in P. vivax infections being frequently treated
Table 2 Prevalence and distribution of pvdhfr, pvdhps and pvmdr1 alleles by province
*pvdhfr pvdhps pvmdr1
Haplotypes No of isolates (%) Haplotypes No of isolates (%) Haplotypes No of isolates (%)
Balochistan IPFSTSI (wild type) 19 (5.7) SAKAV (wild type) 44 (13) YF (wild type) 2 (0.6)
IPFSTNI 18 (5.4) SGKAV 1 (0.3) YL 38 (11)
IPFRTNI 6 (2)
Total sequenced 43/50 45/50 40/50
Islamabad IPFSTSI 26 (7.7) SAKAV 47 (14) YF 3 (1.0)
IPFRTNI 14 (4.2) YL 47 (14)
IPFSTNI 10 (3.0)
Total sequenced 50/50 47/50 50/50
Khyber Pakhtunkhwa IPFSTSI 37 (11) SAKAV 108 (32) YF 5 (2.0)
IPFSTNI 50 (15) SAKGV 1 (0.3) YL 110 (32)
IPFRTNI 22 (6.5) SGKAV 4 (1.2)
IPFRTSI 2 (0.6)
IPLRTSI 1 (0.3)
Total sequenced 112/119 113/119 115/119
Punjab IPFSTSI 55 (16) SAKAV 89 (26) YF 5 (2.0)
IPFRTNI 12 (3.6) SGKAV 1 (0.3) YL 84 (25)
IPFSTNI 12 (3.6) SGKGV 1 (0.3)
IPLRTSI 4 (1.2)
IPFRTSI 1 (0.3)
Total sequenced 84/103 91/103 89/103
Sindh IPFSTSI 14 (4.2) SAKAV 42 (12) YF 2 (0.6)
IPFRTNI 23 (6.8) SGKAV 1 (0.3) YL 46 (14)
IPFSTNI 10 (3.0)
Total sequenced 47/50 43/50 48/50
* Drug resistance-conferring point mutations are shown for the following codons: pvdhfr 13, 33, 57, 58, 61, 117, 173; pvdhps 382, 383, 512, 553, 585; and pvmdr1
976, 1076. Mutated amino acids are shown in bold.
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characterize the current distribution of chloroquine
resistance-associated polymorphisms in pvmdr1 and SP
resistance-associated point mutations in pvdhfr and
pvdhps in Pakistan.
Resistance of P. falciparum to chloroquine is nearly fixed
in Pakistan [3,51], and the emergence of chloroquine-
resistant P. vivax in neighbouring India [52-54] along with
established resistance in Thailand [55,56], Indonesia [57,58]
and Vietnam [59] suggests that the treatment of P. vivax
with chloroquine in Pakistan could be in danger of being
compromised. Clinical trials conducted during 2004-2006
indicate that chloroquine was still efficacious against P.Table 3 Insertions and deletions in pvdhfr gene of Plasmodium
Insertions/Deletions Codons No of bp
Insertion A 91,92 18 bp
Insertion B 103,104 18 bp
Deletion 92,97 18 bpvivax in Pakistan [9]. As a more recent follow-on to clinical
evidence, this study presents the first report of pvmdr1 gene
polymorphisms in Pakistan. Nearly all isolates were wild
type at pvmdr1 Y796F, suggesting that chloroquine resist-
ance in P. vivax has not emerged, but many carried the
F1076L mutant. These results are consistent with previous
studies showing the rise of pvmdr1 F1076L prior to Y976F
[12,23,60]. If the hypothesis that the two-step trajectory of
mutations at codon F1076L followed by Y976F may lead to
chloroquine resistance [12] is correct, then pvmdr1 F1076L
may provide an early signal of emerging chloroquine resist-
ance in Pakistan prior to the appearance of the drug resist-
ance phenotype in the population [22], particularly invivax
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morphisms in pvmdr1 should continue to be monitored in
case the mutation at position Y976F appears. Amplification
of the pvmdr1 gene was not detected in this study,
reflecting the absence of mefloquine drug pressure in
Pakistan. Regions with a history of mefloquine use for fal-
ciparum malaria have shown amplification of both pfmdr1
in P. falciparum and pvmdr1 in P. vivax, likely caused by
inadvertent drug exposure [17,23].
Plasmodium vivax is likely exposed to SP pressure (either
alone or in combination with artesunate) in a bystander ef-
fect, particularly because it is found alongside P. falciparum
in regions with mixed-species infections such as Balochi-
stan (10%), Khyber Pakhtunkhwa (8%), and Punjab (5%)
[42], that are vulnerable to misdiagnosis of Plasmodium
species [3,41,49,51]. Exposure of P. vivax parasites to SP
pressure, with likely subtherapeutic levels in some patients,
could favour the emergence of SP resistance [61].
In this study, the pvdhfr double mutant S58R and
S117N was found in 20% of isolates. The double mutant
has been reported previously from one site in Pakistan
[3] as well as in neighbouring India [62] and Iran [63],
and is associated with in vitro pyrimethamine resistance
[64]. In contrast, point mutations in pvdhps A383G and
A553G were detected in a very small number of samples,
confirming similar results from a previous report in
Bannu district in 2007 [3]. These mutations have also
been reported as rare in Iran [63] and Afghanistan [65],
suggesting that markers associated with sulphadoxine re-
sistance in P. vivax remain rare in this region. Because
SP treatment failure is closely associated with infections
carrying four or more mutations in pvdhfr [35] and add-
itional pvdhps mutations [66], it appears that SP likely
remains efficacious against P. vivax in Pakistan as previ-
ously reported [9].
The prevalence of pvdhfr S117N single and S58R plus
S117N double mutants was highest in Sindh and Khyber
Pakhtunkhwa provinces. Khyber Pakhtunkhwa had the sec-
ond highest prevalence of mixed species and P. falciparum
infections in this survey [42], indicating that perhaps re-
gions with P. falciparum experience higher SP use (with or
without artesunate) that also exerts pressure on co-
occurring P. vivax infections. Khyber Pakhtunkhwa
province also had the highest prevalence of pvmdr1 F1076L
mutants, and may be especially vulnerable to the influx or
emergence of drug-resistant parasites because of the large-
scale migration of Afghan refugees and internally displaced
people (IDPs) from conflict areas to this region, along with
conditions of underdevelopment that may prevent adequate
diagnosis and treatment of malaria [67].
Conclusions
This is the first comprehensive report on molecular pat-
terns of drug resistance in P. vivax in Pakistan. Themajor chloroquine resistance-mediating mutation was
not detected in this study; however continued molecular
monitoring of polymorphisms in pvmdr1 is crucial to
detect the potential emergence of chloroquine-resistant
P. vivax in Pakistan. Although some evidence of pyri-
methamine selective pressure was observed, polymor-
phisms associated with sulphadoxine resistance were
rare, and markers of clinically relevant SP resistance in
P. vivax were not present. Thus, the data on molecular
markers presented here suggest that efficacy of both
chloroquine and SP against P. vivax is currently high,
and can serve as a baseline reference for regional studies
of P. vivax drug sensitivity in Pakistan.
Additional file
Additional file 1: Synonymous and non-synonymous SNPs detected
in pvdhfr, pvdhps and pvmdr1.
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